Order Article Reprints

Yamazaki H, Suzuki G, Masui K, Aibe N, Shimizu D, Kimoto T, Yamada K, Okihara K, Ueda T, Narukawa T, et al. Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10. Cancers. 2022; 14(12):2976. https://doi.org/10.3390/cancers14122976

Yamazaki, Hideya, Gen Suzuki, Koji Masui, Norihiro Aibe, Daisuke Shimizu, Takuya Kimoto, Kei Yamada, Koji Okihara, Takashi Ueda, Tsukasa Narukawa, and et al. 2022. "Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10" Cancers 14, no. 12: 2976. https://doi.org/10.3390/cancers14122976

Yamazaki, H., Suzuki, G., Masui, K., Aibe, N., Shimizu, D., Kimoto, T., Yamada, K., Okihara, K., Ueda, T., Narukawa, T., Shiraishi, T., Fujihara, A., Yoshida, K., Nakamura, S., Kato, T., Hashimoto, Y., & Okabe, H. (2022). Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10. Cancers, 14(12), 2976. https://doi.org/10.3390/cancers14122976